Bryn Mawr Trust Advisors LLC Boosts Stock Position in Becton, Dickinson and Company $BDX

Bryn Mawr Trust Advisors LLC boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 43.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,647 shares of the medical instruments supplier’s stock after buying an additional 14,631 shares during the period. Bryn Mawr Trust Advisors LLC’s holdings in Becton, Dickinson and Company were worth $9,105,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC raised its position in shares of Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after buying an additional 1,354 shares during the period. PFG Investments LLC lifted its holdings in Becton, Dickinson and Company by 32.7% in the second quarter. PFG Investments LLC now owns 2,601 shares of the medical instruments supplier’s stock valued at $448,000 after acquiring an additional 641 shares during the last quarter. Trilogy Capital Inc. purchased a new position in Becton, Dickinson and Company in the second quarter worth approximately $238,000. Finally, USA Financial Formulas increased its stake in Becton, Dickinson and Company by 10.8% during the second quarter. USA Financial Formulas now owns 934 shares of the medical instruments supplier’s stock worth $161,000 after acquiring an additional 91 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.2%

Shares of NYSE BDX opened at $203.56 on Friday. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99. The stock has a market cap of $58.00 billion, a P/E ratio of 34.92, a PEG ratio of 2.22 and a beta of 0.23. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The business’s fifty day simple moving average is $198.54 and its 200-day simple moving average is $191.24.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. During the same quarter last year, the company earned $3.81 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.1%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is 72.04%.

Becton, Dickinson and Company announced that its board has authorized a stock repurchase program on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

Several equities analysts have recently commented on BDX shares. Jefferies Financial Group upped their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Bank of America boosted their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Piper Sandler increased their price objective on shares of Becton, Dickinson and Company from $190.00 to $205.00 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $209.00.

Insider Buying and Selling

In related news, Director Bertram L. Scott sold 217 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 2,680 shares of company stock worth $539,848. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.